PLXP · Plx Pharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $753.1K | $778.7K | $0 |
| Cost of Revenue | $0 | - | - | - | - | - |
| Gross Profit | $30.0K | - | - | - | - | - |
| R&D | $4.18M | $4.34M | $4.74M | $3.92M | $78.7K | $12.75M |
| SG&A | $9.15M | $9.15M | $10.03M | $7.79M | $10.17M | $8.61M |
| Total Operating Expenses | $44.19M | $13.49M | $14.77M | $11.71M | $16.63M | $21.37M |
| D&A | $116.0K | $124.6K | $158.3K | $201.0K | $3.3K | - |
| Operating Income | ($40.79M) | ($13.46M) | ($14.20M) | ($10.96M) | ($15.85M) | ($21.37M) |
| Interest Expense | - | $307.9K | $995.0K | $1.15M | $95.1K | - |
| Income Tax | $0 | - | - | - | ($920.0K) | - |
| Net Income | ($46.13M) | ($15.21M) | ($20.50M) | $896.5K | ($15.35M) | ($21.32M) |
| EPS - Basic | - | ($1.74) | ($3.84) | ($2.19) | - | - |
| EPS - Diluted | - | $9714951.00 | ($3.84) | $0.10 | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $69.39M | $22.45M | $14.00M | $14.25M | $24.40M | $16.68M |
| Accounts Receivable | $634.0K | - | $18.7K | $18.2K | $19.4K | - |
| Inventory | $2.46M | $100.0K | $0 | - | $246.4K | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $73.48M | $22.99M | $14.28M | $14.87M | $25.69M | $17.03M |
| Total Assets | $76.64M | $26.62M | $18.50M | $18.39M | $28.85M | $17.09M |
| Current Liabilities | $11.88M | $3.54M | $6.09M | $4.73M | $1.82M | - |
| Long-term Debt | - | - | $622.3K | $4.28M | $6.94M | - |
| Total Liabilities | $24.96M | $16.16M | $16.93M | $11.94M | $24.23M | $2.12M |
| Stockholders' Equity | $35.67M | ($10.93M) | ($12.09M) | $6.44M | $4.62M | $14.97M |
| Retained Earnings | ($148.27M) | ($102.15M) | ($86.94M) | ($66.44M) | ($67.33M) | ($62.38M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($32.12M) | ($12.24M) | ($12.66M) | ($9.50M) | ($1.81M) | ($15.58M) |
| Investing Cash Flow | $95.0K | ($102.0K) | ($230.3K) | ($654.9K) | $11.24M | $27.02M |
| Financing Cash Flow | $78.97M | $20.79M | $12.64M | - | $1.78M | $0 |
| CapEx | - | $102.0K | $241.7K | $654.9K | $537.6K | - |
| Free Cash Flow | - | ($12.35M) | ($12.90M) | ($10.15M) | ($2.35M) | - |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | -1455.5% | -2035.3% | - |
| EBITDA margin | - | - | - | -1428.8% | -2034.9% | - |
| Net margin | - | - | - | 119.0% | -1970.9% | - |
| Free cash flow margin | - | - | - | -1348.3% | -301.5% | - |
| FCF / Net income | - | 0.81 | 0.63 | -11.33 | 0.15 | - |
| R&D / Revenue | - | - | - | 520.9% | 10.1% | - |
| SG&A / Revenue | - | - | - | 1034.6% | 1306.7% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -60.2% | -57.1% | -110.8% | 4.9% | -53.2% | -124.8% |
| Return on equity | -129.3% | 139.1% | 169.6% | 13.9% | -332.4% | -142.4% |
| Return on invested capital | - | - | - | - | -108.3% | - |
| Liquidity | ||||||
| Current ratio | 6.19 | 6.49 | 2.34 | 3.14 | 14.15 | - |
| Quick ratio | 5.98 | 6.46 | 2.34 | 3.14 | 14.01 | - |
| Cash ratio | 5.84 | 6.34 | 2.30 | 3.01 | 13.44 | - |
| Leverage | ||||||
| Debt / Equity | - | - | -0.05 | 0.66 | 1.50 | - |
| Debt / Assets | - | - | 0.03 | 0.23 | 0.24 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -43.7x | -14.3x | -9.6x | -166.6x | - |
| Equity multiplier | 2.15 | -2.43 | -1.53 | 2.85 | 6.25 | 1.14 |
| Liabilities / Assets | 0.33 | 0.61 | 0.92 | 0.65 | 0.84 | 0.12 |
| Efficiency | ||||||
| Asset turnover | - | - | - | 0.04 | 0.03 | 0.00 |
| Inventory turnover | 0.00 | - | - | - | - | - |
| Days sales outstanding | - | - | - | 9d | 9d | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | -3.3% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -203.1% | 5.2% | -29.6% | 30.8% | 25.8% | -13.9% |
| Net income growth (YoY) | -203.2% | 25.8% | - | - | 28.0% | -13.8% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 4.3% | -27.0% | -332.5% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 9.6% | - | 39.6% | -69.2% | 366.9% |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PLx Pharma Inc. against the 5 most active filers in the same SIC group.